Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-0159 in Prurigo Nodularis
NCT04944862Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of barzolvolimab in prurigo nodularis (PN) (3 arms), sponsored by Celldex Therapeutics. Primary endpoint: Incidence and severity of adverse events. Started Nov 2021; status: completed.
02
Drugs
barzolvolimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT04944862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944862.